Molecular Targeting Technologies, Inc.
West Chester
Pennsylvania
United States
Tel: 610-738-7938
Fax: 610-738-7928
Website: http://www.mtarget.com/
23 articles about Molecular Targeting Technologies, Inc.
-
Molecular Targeting Technologies, Inc. to Present EvaThera, Long-Acting Peptide Receptor Radionuclide Therapy Platform, at BioFuture™ 2023
10/5/2023
Molecular Targeting Technologies, Inc., is presenting at BioFuture 2023 on Thursday 2:45 PM, Oct 5th, at Lotte New York Palace hotel.
-
MTTI Announces the Appointment of Dr. Jerry Huang to the Clinical Team
9/12/2023
Molecular Targeting Technologies, Inc., a clinical-stage company accelerating the development and global access of life-changing radiopharmaceuticals, announced the appointment of Dr. Jerry Huang, M.D., Ph.D. as the Senior Vice President of Clinical Development.
-
Molecular Targeting Technologies, Inc. and Molecular Theranostics Center of Singapore Receive HSA Approval for Clinical Trial Authorization for EBTATE® in Nasopharyngeal Cancer
8/2/2023
Molecular Targeting Technologies, Inc., and its wholly owned subsidiary, Molecular Theranostic Center of Singapore, announced the approval of a Clinical Trial Authorization application by the Health Sciences Authority of Singapore.
-
MTTI Highlights Promising One-Year Follow-Up on EBTATE Treatment of Neuroendocrine Cancer Patients Without Amino Acid Infusion
6/21/2023
Molecular Targeting Technologies, Inc. announced promising results from a 1-year follow-up on EBTATE treatment of gastroenteropancreatic neuroendocrine tumors without amino acid pretreatment.
-
MTTI Announces Favorable Three-Year Follow-Up for EBTATE in Neuroendocrine Tumors
6/19/2023
Molecular Targeting Technologies, Inc. announced favorable findings of a 3-year follow-up of EBTATE against metastatic gastroenteropancreatic neuroendocrine tumors.
-
MTTI Obtains FDA Allowance of Investigational New Drug (IND) for Hürthle Cell Thyroid Cancer
12/8/2022
Molecular Targeting Technologies, Inc. (MTTI), a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the allowance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA).
-
MTTI Receives Chinese Patent for EVATHERA Technology
12/6/2022
Molecular Targeting Technologies, Inc. announces the issuance of Chinese Patent CN109153641B covering MTTI’s lead radiotherapeutic product, EBTATE™ and others in its EvaThera™ platform.
-
MTTI Doses First Patient in EBTATE Neuroendocrine Tumor Clinical Trial
6/29/2022
Molecular Targeting Technologies, Inc. (MTTI), announced that the first patient has been dosed in a clinical trial of EBTATE ( 177 Lu-DOTA-EB-TATE) for the treatment of patients with advanced, well differentiated neuroendocrine tumors.
-
Molecular Targeting Technologies, Inc. Features EBTATE Advances at The 2022 SNMMI Meeting In Vancouver, BC
6/9/2022
Molecular Targeting Technologies, Inc. (MTTI), a clinical stage oncology company, will highlight advances on its EvaThera TM radiotheranostics platform at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting in Vancouver, BC, on June 11-15, 2022.
-
MTTI and ITM Sign Clinical Supply Agreement for n.c.a. Lutetium-177
4/13/2022
Molecular Targeting Technologies Inc. and ITM Isotope Technologies Munich SE announced the signing of a global clinical supply agreement that provides MTTI with ITM’s medical radioisotope no-carrier-added lutetium-177 for the preclinical and clinical development as well as potential commercial production of MTTI’s radiopharmaceutical candidate n.c.a.
-
Molecular Targeting Technologies, Inc., Thomas Jefferson University and North China Pharmaceutical Co., Ltd Announced the Chinese Approval for a Rabies Drug
1/26/2022
Molecular Targeting Technologies, Inc., (MTTI) announced that the Chinese NMPA has approved a rabies virus neutralizing, fully human antibody, Ormutivimab for post-exposure prophylaxis.
-
MTTI partners with Evergreen to manufacture EvaThera platform of radiopharmaceuticals
12/1/2021
Molecular Targeting Technologies, Inc. (MTTI) and Evergreen Theragnostics, Inc., today announced an agreement in which Evergreen will manufacture MTTI's EvaThera™ platform of radiopharmaceuticals.
-
Molecular Targeting Technologies, Inc. Announces Spray Technology That Lights Up Tumors
10/19/2021
Molecular Targeting Technologies, Inc. (MTTI) announce publication of their Spray technology in ACS Sensors, entitled “Near-Infrared Fluorogenic Spray for Rapid Tumor Sensing.”
-
Molecular Targeting Technologies, Inc. and University of Antwerp Begin First-in-Human Study of TDURA Diagnostic for Early Detection of Response to Colon Cancer Therapy
5/11/2021
Molecular Targeting Technologies, Inc. (MTTI) and University of Antwerp today announced the approval of a Clinical Trial Application by the European Federal Agency for Medicines and Health Products (FAMHP) (equivalent to a US IND). The clinical study will evaluate the safety, dosimetry and treatment response of TDURA ( 99m Tc-Duramycin), in patients with advanced colorectal cancer (CRC)*.
-
Molecular Targeting Technologies, Inc. Receives Global Rights From NIH for Integrin-Targeting Radiotherapeutics to Treat GBM and Lung Cancer
10/28/2019
The key feature of this technology is the incorporation of a derivative of Evans Blue into RGD peptide radiopharmaceutical which binds to both albumin and integrin thus extends residence time, enabling smaller and less frequent dosing.
-
Early Studies Show EBTATE is Well Tolerated and Effective in Treating Neuroendocrine Tumors
6/24/2019
Talk entitled “Safety and Response of an Evans Blue-modified 177Lu-labeled Octreotate (EBTATE) in Treatment of Metastatic Neuroendocrine Tumors: A Pilot Prospective Study” at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Anaheim this June*.
-
Molecular Targeting Technologies, Inc. Wins Exclusive License for Novel Neuroendocrine Neoplasm Drug from NIH
10/8/2018
This patent estate invented by Drs. Xiaoyuan Chen and Orit Jacobson covers a radiotherapeutic with potential uses for treating Neuroendocrine Neoplasms
-
Molecular Targeting Technologies, Inc. Receives Expanded Patent Approval For 99mTC-Duramycin Technology To Target Programmed Cell Death
5/18/2015
-
Molecular Targeting Technologies, Inc. And National Health Research Institutes Present A Novel Cancer Therapeutic At 2015 American Association for Cancer Research
4/17/2015
-
Molecular Targeting Technologies, Inc. And National Health Research Institutes Have Joined Forces In Developing Novel Cancer Therapeutics
8/5/2014